The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Open accessAbstract
Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium-specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The techniques underpinning AAV-mediated retinal gene therapy have undergone iterative improvement since the first-in-human studies in RPE65 -associated IRDs (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2008
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Dose finding studies have shown that a high number of rAAV particles (>10 12 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredIn the citing paper
“Direct injection into the subretinal space, as was the route for the first FDA-approved AAV vector, results in less exposure to plasma proteins, circulating antibodies, blood cells, and tissue-resident phagocytic cells [15].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [15]
In the citing paper
“Gene therapy gained its place in mainstream medical practice following FDA approval of Luxturna, an AAV2- based treatment for the inherited retinal disease (IRD) retinal pigment epithelium (RPE)65-LCA (LCA2).”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“Treated patients exhibited life-changing improvements in light sensitivity and visually guided behavior.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“CNS-directed AAV delivery has been associated with an increase in inflammatory mediators, including neutralizing antibodies, circulating CD45+ leukocytes, natural killer cells, and CD8+ and CD4+ T cells.13,14,15,16,17,18,19”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Morimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481
Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Thompson DA, 2000, Invest Ophthalmol Vis Sci, 41, 4293
- Znoiko SL, 2002, Invest Ophthalmol Vis Sci, 43, 1604
- 10.1038/88327 · DOI
Cited by
Sorted by citations
Items 901–1,000 of 1,016
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 27
Ishibashi, Y., Sung, C. Y. W., Grati, M., & Chien, W. W. (2023) · Hearing Research · doi:10.1016/j.heares.2023.108735 · Cited by 28
Beyond traditional pharmacology: new tools and approaches
Gurevich, E. V., & Gurevich, V. V. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13066 · Cited by 28
A reliable and feasible qPCR strategy for titrating AAV vectors
Wang, F., Cui, X., Wang, M., Xiao, W., & Xu, R. (2013) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.883968 · Cited by 28
Lee, G. H., & Kim, S. S. (2016) · Mediators of Inflammation · doi:10.1155/2016/5808215 · Cited by 27
pEPito-driven PEDF Expression Ameliorates Diabetic Retinopathy Hallmarks
Calado, S. M., Diaz-Corrales, F. J. J., & Silva, G. A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.169 · Cited by 27
Shin, Y., Moiseyev, G. P., Chakraborty, D., & Ma, J. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.11.004 · Cited by 27
Yeh, C. Y., Koehl, K. L., Harman, C. D., Iwabe, S., Guzman, J. M., Petersen‐Jones, S. M., Kardon, R. H., & Komáromy, A. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19865 · Cited by 28
Self-citationTraboulsi, E. I. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.165654 · Cited by 27
Caruso, R. C., Aleman, T. S., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Mullins, C. L., Boye, S. L., Hauswirth, W. W., & Jacobson, S. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5559 · Cited by 26
Daruich, A., Rateaux, M., Batté, E., de Vergnes, N., Valleix, S., Robert, M. P. A., & Brémond‐Gignac, D. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-326221 · Cited by 26
Improvement in vision: a new goal for treatment of hereditary retinal degenerations
Jacobson, S. G., Cideciyan, A. V., Aguirre, G. D., Román, A. J., Sumaroka, A., Hauswirth, W. W., & Palczewski, K. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1030393 · Cited by 26
Bronstein, R., Capowski, E. E., Mehrotra, S., Jansen, A. D., Navarro-Gomez, D., Maher, M., Place, E., Sangermano, R., Bujakowska, K. M., Gamm, D. M., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa016 · Cited by 27
Alemán, T. S., Miller, A. J., Maguire, K. H., Aleman, E. M., Serrano, L. W., O’Connor, K., Bedoukian, E. C., Leroy, B. P., Maguire, A. M., & Bennett, J. (2021) · Clinical ophthalmology · doi:10.2147/opth.s292527 · Cited by 26
Shmidt, A. A., & Egorova, T. V. (2021) · Pharmaceuticals · doi:10.3390/ph15010023 · Cited by 27
Valdés-Sánchez, L., Borrego-González, S., Montero-Sánchez, A., Massalini, S., de la Cerda, B., Díaz‐Cuenca, A., & Diaz-Corrales, F. J. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082170 · Cited by 26
Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision
Karamali, F., Behtaj, S., Abraki, S. B., Hadady, H., Atefi, A., Savoj, S., Soroushzadeh, S., Najafian, S., Nasr‐Esfahani, M. H., & Klassen, H. J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03738-4 · Cited by 27
Nano-vectors for the ocular delivery of nucleic acid-based therapeutics
Khar, R. K., Warsi, M. H., Akhter, S., Ahmad, F., Jain, G. K., Mallick, N., & Pathan, S. (2010) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.84575 · Cited by 26
Gene Therapy Regenerates Protein Expression in Cone Photoreceptors in Rpe65R91W/R91W Mice
Kostic, C., Crippa, S. V., Pignat, V., Bemelmans, A., Samardzija, M., Grimm, C., Wenzel, A., & Arsenijévic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016588 · Cited by 26
Optopharmacological tools for restoring visual function in degenerative retinal diseases
Tochitsky, I., & Krämer, R. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.01.018 · Cited by 26
Limb, G. A., & Martin, K. R. G. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6894 · Cited by 26
Buclez, P.-O., Leite, G. D. F., Relizani, K., Beley, C., García, L., & Benchaouir, R. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.35 · Cited by 26
Barny, I., Perrault, I., Michel, C., Goudin, N., Defoort‐Dhellemmes, S., Ghazi, I., Kaplan, J., Rozet, J., & Gérard, X. (2019) · Genes · doi:10.3390/genes10050368 · Cited by 26
Lee, S. H., Sim, K. S., Kim, C. Y., & Park, T. K. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.009 · Cited by 26
Chitosan microparticles for delivery of proteins to the retina
Wassmer, S., Rafat, M., Fong, W. G., Baker, A. N., & Tsilfidis, C. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.04.025 · Cited by 26
Recent advances in ocular gene therapy
Chung, D. C., Lee, V., & Maguire, A. M. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32832f802a · Cited by 26
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 26
Pfau, M., Lindner, M., Steinberg, J. S., Thiele, S., Brinkmann, C. K., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311012 · Cited by 25
The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy
Zhang, Y., Tian, Z., Yuan, J., Liu, C. X., Liu, H. L., Qi, S., & Li, B. (2018) · Current Gene Therapy · doi:10.2174/1566523218666171129204926 · Cited by 25
Development of a Gene Therapy Vector for RDH12 -Associated Retinal Dystrophy
Feathers, K. L., Jia, L., Perera, N. D., Chen, A., Presswalla, F., Khan, N., Fahim, A. T., Smith, A. J., Ali, R. R., & Thompson, D. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.017 · Cited by 25
Self-citationWard, R. H. R., Kaylor, J. J., Cobice, D., Pepe, D. A., McGarrigle, E. M., Brockerhoff, S. E., Hurley, J. B., Travis, G. H., & Kennedy, B. N. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011374 · Cited by 25
Aronson, S. J., Bakker, R. S., Moenis, S., van Dijk, R., Bortolussi, G., Collaud, F., Shi, X., Duijst, S., ten Bloemendaal, L., Ronzitti, G., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.002 · Cited by 25
Recent Progress in Photoreceptor Cell-Based Therapy for Degenerative Retinal Disease
Klymenko, V., Martinez, O. G. G., & Zarbin, M. A. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae005 · Cited by 26
Channelrhodopsins: visual regeneration and neural activation by a light switch
Natasha, G., Tan, A., Farhatnia, Y., Rajadas, J., Hamblin, M. R., Khaw, P. T., & Seifalian, A. M. (2013) · New Biotechnology · doi:10.1016/j.nbt.2013.04.007 · Cited by 28
Brendel, C., Haenseler, W., Wohlgensinger, V., Bianchi, M., Tokmak, S., Chen-Wichmann, L., Kuzmenko, E. S., Cesarovic, N., Nicholls, F., Reichenbach, J., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.157 · Cited by 26
Silva, G. A., Oliveira, A. V., Silva, A., Bitoque, D. B., & da Costa, A. M. R. (2013) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.111823 · Cited by 25
Kármán, J., Gumlaw, N., Zhang, J., Jiang, J.-L., Cheng, S. H., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034684 · Cited by 26
DNA as therapeutics; an update
Saraswat, P., Soni, R., Bhandari, A., & Nagori, B. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.58169 · Cited by 28
Kim, J.-S., Chu, H. S., Park, K., Won, J.-I., & Jang, J.-H. (2011) · Gene Therapy · doi:10.1038/gt.2011.84 · Cited by 25
Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives
Katz, M. G., Fargnoli, A. S., Kendle, A. P., Hajjar, R. J., & Bridges, C. R. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.12.004 · Cited by 25
Dasari, B., Cashman, S. M., & Kumar‐Singh, R. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.004 · Cited by 25
Assessment of Central Visual Function in Patients with Retinitis Pigmentosa
Fujiwara, K., Ikeda, Y., Murakami, Y., Tachibana, T., Funatsu, J., Koyanagi, Y., Nakatake, S., Yoshida, N., Nakao, S., Hisatomi, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26231-9 · Cited by 25
Bennett, J., & Maguire, A. M. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041307 · Cited by 25
Hu, J., & Bok, D. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60327-325-1_2 · Cited by 24
Petit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Early clinical evidence further supports the use of immunomodulation to prevent and treat GTAU in the context of IRDs, discussed below.”
InfluentialSelf-citationDai, X., Han, J., Qi, Y., Zhang, H., Xiang, L., Lv, J., Li, J., Deng, W., Chang, B., Hauswirth, W. W., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13654 · Cited by 24
viringipurampeer, I. A., Gregory, C. Y., Metcalfe, A. L., Bashar, E., Moritz, O. L., & Gregory-Evans, K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1192-8 · Cited by 27
CNGB1 ‐related rod‐cone dystrophy: A mutation review and update
Nassisi, M., Smirnov, V. M., Hernandez, C. S., Mohand‐Saïd, S., Condroyer, C., Antonio, A., Kuehlewein, L., Kempf, M., Kohl, S., Wissinger, B., et al. (2021) · Human Mutation · doi:10.1002/humu.24205 · Cited by 24
Self-citationAdeno-associated virus serotype-9 efficiently transduces the retinal outer plexiform layer.
Lei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · PubMed Central · Cited by 24
Kenny, G., Villegas-Llerena, C., Tagalakis, A., Campbell, F., Welser, K., Botta, M., Tabor, A., Hailes, H., Lythgoe, M., & Hart, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.042 · Cited by 24
Tian, L., Lei, B., Shao, J., Wei, L., Kijlstra, A., & Yang, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037995 · Cited by 24
Flotte, T. R. (2013) · Molecular Therapy · doi:10.1038/mt.2013.226 · Cited by 24
Gene therapy as a new treatment option for inherited monogenic diseases
Boudes, P. F. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.009 · Cited by 28
Current prospects and challenges for epilepsy gene therapy
Weinberg, M. S., & McCown, T. J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.003 · Cited by 24
Channelrhodopsins provide a breakthrough insight into strategies for curing blindness
Tomita, H., Sugano, E., Isago, H., & Tamai, M. (2009) · Journal of Genetics · doi:10.1007/s12041-009-0062-6 · Cited by 24
Terapia gênica: o que é, o que não é e o que será
Linden, R. (2010) · Estudos Avançados · doi:10.1590/s0103-40142010000300004 · Cited by 29
Sundaram, V., Moore, A. T., Ali, R. R., & Bainbridge, J. W. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1615-2 · Cited by 24
Self-citationLi, S., Samardzija, M., Yang, Z., Grimm, C., & Jin, M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3857-15.2016 · Cited by 26
Pluripotent stem cells and their utility in treating photoreceptor degenerations
Aghaizu, N. D., Kruczek, K., Gonzalez-Cordero, A., Ali, R. R., & Pearson, R. A. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2017.01.001 · Cited by 25
Self-citationConcepts and Strategies in Retinal Gene Therapy
Aguirre, G. D. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22978 · Cited by 24
Song, J. Y., Aravand, P., Nikonov, S. S., Leo, L., Lyubarsky, A., Bennicelli, J. L., Pan, J., Wei, Z., Shpylchak, I., Herrera, P. S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.015 · Cited by 24
Ocular delivery of solid lipid nanoparticles
Battaglia, L., Gallarate, M., Serpe, L., Foglietta, F., Muntoni, E., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813687-4.00007-4 · Cited by 24
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 25
Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview
Kumaran, N., Pennesi, M. E., Yang, P. G., Trzupek, K. M., Schlechter, C. L., Moore, A. T., Weleber, R. G., & Michaelides, M. (2018) · Europe PMC (PubMed Central) · Cited by 24
Self-citationThe new landscape of retinal gene therapy
Ku, C. A., & Pennesi, M. E. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31842 · Cited by 24
Campbell, J. P., McFarland, T. J., & Stout, J. T. (2015) · Developments in ophthalmology · doi:10.1159/000434698 · Cited by 24
Subretinal Delivery and Electroporation in Pigmented and Nonpigmented Adult Mouse Eyes
Nickerson, J. M., Goodman, P., Chrenek, M. A., Bernal, C. J., Berglin, L., Redmond, T. M., & Boatright, J. H. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-848-1_4 · Cited by 25
Gene therapy strategies for cardiac electrical dysfunction
Greener, I. D., & Donahue, J. K. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.07.022 · Cited by 24
Hai, B., Yan, X., Voutetakis, A., Zheng, C., Cotrim, A. P., Shan, Z., Ding, G., Zhang, C., Xu, J., Goldsmith, C. M., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1319 · Cited by 24
Touchard, E., Kowalczuk, L., Bloquel, C., Naud, M., Bigey, P., & Béhar‐Cohen, F. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1517 · Cited by 24
Marginal integrity of self- and total-etching adhesives in two different application protocols.
Ernsta, C.-P., Kötter, T., Victor, A., Canbek, K., Brandenbusch, M., & Willershausen, B. (2004) · PubMed · Cited by 24
Matet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis
van der Marel, S. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i32.4288 · Cited by 23
Fuentes, C., & Schaffer, D. V. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.003 · Cited by 27
New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies
Pulman, J., Sahel, J., & Dalkara, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0141 · Cited by 25
KIF11 UFMylation Maintains Photoreceptor Cilium Integrity and Retinal Homeostasis
Ran, J., Guo, G., Zhang, S., Zhang, Y., Zhang, L., Li, D., Wu, S., Cong, Y., Wang, X., Xie, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202400569 · Cited by 23
Communicating the Promise for Ocular Gene Therapies: Challenges and Recommendations
Benjaminy, S., Kowal, S. P., MacDonald, I. M., & Bubela, T. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.05.026 · Cited by 24
Mansergh, F. C., Vawda, R., Millington‐Ward, S., Kenna, P. F., Haas, J., Gallagher, C., Wilson, J. H., Humphries, P., Ader, M., & Farrar, G. J. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.07.003 · Cited by 23
Phenotype-Genotype Correlations in Autosomal Dominant Retinitis Pigmentosa Caused by RHO, D190N
Tsui, I., Chou, C. L., Palmer, N., Lin, C., & Tsang, S. H. (2008) · Current Eye Research · doi:10.1080/02713680802484645 · Cited by 23
Mao, Y., Kiss, S., Boyer, J. L., Hackett, N. R., Qiu, J., Carbone, A. D., Mezey, J. G., Kaminsky, S. M., D’Amico, D. J., & Crystal, R. G. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.090 · Cited by 23
Gene therapy: light is finally in the tunnel
Cao, H., Molday, R. S., & Hu, J. (2011) · Protein & Cell · doi:10.1007/s13238-011-1126-y · Cited by 26
iPS Cells for Modelling and Treatment of Retinal Diseases
Chen, F. K., McLenachan, S., Edel, M. J., da Cruz, L., Coffey, P. J., & Mackey, D. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3041511 · Cited by 27
Redefining tissue engineering for nanomedicine in ophthalmology
Ellis-Behnke, R. G., & Jonas, J. B. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.01982.x · Cited by 23
Favaro, P. M. B., Finn, J. D., Siner, J. I., Wright, J. F., High, K. A., & Arruda, V. R. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.155 · Cited by 23
Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector
Srivastava, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29017.asr · Cited by 23
Mesenchymal stem cells in regenerative rehabilitation
Nurković, J., Dolicanin, Z. C., Mustafić, F., Mujanović, R., Memic, M., Grbovic, V. M., Jurišić-Škevin, A., & Nurković, S. (2016) · Journal of Physical Therapy Science · doi:10.1589/jpts.28.1943 · Cited by 23
Huang, H., Chen, Y., Chen, H., Ma, Y., Chiang, P.-W., Zhong, J., Liu, X., Asan, Wu, J., Su, Y. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0185237 · Cited by 23
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Gene Therapy to the Retina and the Cochlea
Crane, R., Conley, S. M., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.652215 · Cited by 24
Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho−/− mouse
Palfi, A., Chadderton, N., O’Reilly, M., Nagel‐Wolfrum, K., Uwe Wolfrum, B., Bennett, J., Humphries, P., Kenna, P. F., Millington‐Ward, S., & Farrar, J. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.16 · Cited by 23
Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Kohno, R.-I., Murakami, Y., Murata, T., Tabata, T., Ueda, Y., Ono, F., Suzuki, T., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.009 · Cited by 23
Experimental gene transfer to the corneal endothelium
Kampik, D., Ali, R. R., & Larkin, F. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.07.001 · Cited by 24
Self-citationWatson, C. M., El‐Asrag, M. E., Parry, D. A., Morgan, J., Logan, C. V., Carr, I., Sheridan, E. G., Charlton, R. S., Johnson, C. A., Taylor, G. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104281 · Cited by 23
Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Liu, Y., Siriwon, N., Rohrs, J. A., & Wang, P. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531171653 · Cited by 24
Lin, M. K., Tsai, Y.-T., & Tsang, S. H. (2015) · PubMed · Cited by 22
Arya, B., Westcott, M. C., Robson, A. G., Holder, G. E., & Pavesio, C. E. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306003 · Cited by 22
Self-citationBringing next-generation therapeutics to the clinic through synthetic biology
Bugaj, L. J., & Schaffer, D. V. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.04.009 · Cited by 22
Amamoto, R., Wallick, G. K., & Cepko, C. L. (2022) · eLife · doi:10.7554/elife.76389 · Cited by 22
Cao, X., Yung, J., Mak, H., & Leung, C. K. S. (2019) · Gene Therapy · doi:10.1038/s41434-019-0060-0 · Cited by 20
Metadata
- Authors
- Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- University College London (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2231-2239
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151809142
- Cited by
- 1,924
- References
- 25
- Citations by year
- 2026: 22 · 2025: 43 · 2024: 47 · 2023: 57 · 2022: 61 · 2021: 94 · 2020: 97 · 2019: 83 · 2018: 101 · 2017: 115 · 2016: 98 · 2015: 155 · 2014: 142 · 2013: 149 · 2012: 151
- FWCI
- 69.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, subretinal injection, retinal dystrophy, visual function, microperimetry, visual acuity, electroretinogram
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
